Celltrion, Inc. – Product Pipeline Review – Q2 2011
Global Market Direct’s pharmaceuticals report, “Celltrion, Inc. - Product Pipeline Review - Q2 2011” provides data on the Celltrion, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Celltrion, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Celltrion, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Celltrion, Inc. - Brief Celltrion, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Celltrion, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Celltrion, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Celltrion, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Celltrion, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Celltrion, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Celltrion, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows
Celltrion, Inc. – Product Pipeline Review – Q2 2011 Reference Code: GMDHC1282CDB Publication Date: JULY 2011 Celltrion, Inc. – Product Pipeline Review – Q2 2011 GMDHC1282CDB / Published JULY 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Celltrion, Inc. – Product Pipeline Review Ta b le o f Co n te n ts Table of Contents 2 List of Tables 4 List of Figures 4 Celltrion, Inc. Snapshot 5 Celltrion, Inc. Overview 5 Key Information 5 Key Facts 5 Celltrion, Inc. – Research and Development Overview 6 Key Therapeutic Areas 6 Celltrion, Inc. – Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products – Monotherapy 10 Pipeline Products – Combination Treatment Modalities 11 Celltrion, Inc. – Pipeline Products Glance 12 Celltrion, Inc. – Late Stage Pipeline 12 Phase III Products/Combination Treatment Modalities 12 Celltrion, Inc.–Early Stage Pipeline Products 13 Pre-Clinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Celltrion, Inc. – Drug Profiles 15 CT-P06 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Herceptin + Paclitaxel 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CT-P13 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CT-P15 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CT-P05 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CT-P10 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CT-P14 21 Product Description 21 Celltrion, Inc. – Product Pipeline Review – Q2 2011 GMDHC1282CDB/ Published JULY 2011 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2) Celltrion, Inc. – Product Pipeline Review Mechanism of Action 21 R&D Progress 21 CT-P16 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CT-P17 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CT-P19 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CT-P22 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Celltrion, Inc. – Pipeline Analysis 26 Celltrion, Inc. – Pipeline Products by Therapeutic Class 26 Celltrion, Inc. - Pipeline Products By Target 28 Celltrion, Inc. – Pipeline Products by Route of Administration 30 Celltrion, Inc. – Pipeline Products by Molecule Type 31 Celltrion, Inc. – Company Statement 32 Celltrion, Inc. – Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Financial Deals Landscape 34 Celltrion, Inc., Deals Volume Summary, 2004 to YTD 2011 34 Celltrion, Inc., Deals Summary By Region, 2004 to YTD 2011 35 Celltrion, Inc., Deals Summary, 2004 to YTD 2011 36 Celltrion
Pages to are hidden for
"Celltrion, Inc. – Product Pipeline Review – Q2 2011"Please download to view full document